Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy
These preclinical results establish maplirpacept as an effective CD47 blocker that mitigates the potential for anemia in patients.
Authors
- Keith Abayasiriwardana (ORCID: https://orcid.org/0009-0002-0984-2485)
- Natasja Nielsen Viller
- Mark Wong
- Gloria H. Y. Lin (ORCID: https://orcid.org/0000-0001-5503-9031)
- Jean Wang (ORCID: https://orcid.org/0000-0001-7543-3917)
- Robert A. Uger (ORCID: https://orcid.org/0000-0002-0569-3307)
- Mithunah Krishnamoorthy (ORCID: https://orcid.org/0000-0003-2556-5457)
- Lisa D. Johnson (ORCID: https://orcid.org/0000-0002-2019-6560)
- Megan M. Kaneda
- Christopher P. Dillon (ORCID: https://orcid.org/0000-0002-9458-0266)
- Clare Lees
- Ruth Seelige
- Emma Linderoth
- Christopher R. Brown (ORCID: https://orcid.org/0000-0001-6292-2738)
- Nicole G. Chau
Institutions
- University Health Network (CA)
- Pfizer (United States) (US)
- University of Toronto (CA)
- Princess Margaret Cancer Centre (CA)
- Trillium Therapeutics (Canada) (CA)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.3389/fimmu.2025.1518787
- Citations
- 4
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 3.19